To Be Discontinued Capsule Hematology
Anagrelide Hydrochloride Cap · 296 days since initial FDA posting
FDA lists Anagrelide Hydrochloride Cap as To Be Discontinued (Teva Pharmaceuticals USA, Inc.).
No availability text on this FDA row.
Anagrelide Hydrochloride Capsule: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Anagrelide Hydrochloride Capsule
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Dosage Form
- Capsule
- Presentation
- Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60)
- Package NDC
- 0172-5241-60
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Nov 19, 2025
- Last Updated
- Nov 19, 2025
- Therapeutic Category
- Hematology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
A business decision was made to discontinue manufacture of the drug.
Nearby, Other Anagrelide Shortage Records
FDA reason on file: A business decision was made to discontinue manufacture of the drug. General shortage guidance lives on the tracker hub.